FIGS Raises FY26 Sales Guidance to $757.3M, Beating Estimates
FIGS Inc raised its FY26 sales guidance to $757.318 million, up from a prior range of $719.452 million to $732.074 million. The new outlook also beats the market estimate of $729.093 million, reflecting strong business momentum.

*this image is generated using AI for illustrative purposes only.
FIGS Inc has raised its sales guidance for fiscal year 2026, signaling stronger-than-expected demand for its professional apparel. The company now expects total revenue of $757.318 million for the period, a significant upward revision from its previous outlook.
The new guidance exceeds the earlier projected range of $719.452 million to $732.074 million. Furthermore, the updated figure beats the consensus market estimate of $729.093 million, indicating that FIGS is outperforming analyst expectations for the current fiscal cycle.
Guidance Revision Details
The revision reflects improved visibility into future sales performance. Below is a comparison of the updated guidance against prior expectations:
| Metric | Value |
|---|---|
| New FY26 Sales Guidance | $757.318 million |
| Prior Guidance Range | $719.452 million - $732.074 million |
| Market Estimate | $729.093 million |
What the Numbers Show
The upward adjustment suggests robust underlying momentum in FIGS' core business segments. By raising the midpoint of its guidance significantly above the initial range, the company demonstrates confidence in its ability to capture additional market share or drive higher volume in the remaining quarters of FY26. The fact that the new target clears the external estimate by nearly $28 million underscores a positive divergence between internal operational performance and broader market sentiment.
What specific product lines or geographic regions are driving the stronger-than-expected demand for FIGS' professional apparel?
How might this upward revision in FY26 guidance influence FIGS' valuation multiples and stock price trajectory in the near term?
Will FIGS consider accelerating its expansion into new international markets or adjacent healthcare sectors given this increased revenue visibility?

























